Allergan has announced that AGN-190584 (pilocarpine 1.25%) ophthalmic solution for presbyopia treatment met its primary and secondary endpoints in its phase 3 Gemini 1 clinical study.  

The company said a statistically significant greater proportion of presbyopic patients using the drops achieved near and intermediate vision gains of at least three lines without compromising distance vision. It also said the drops acted within 15 minutes and their effects were sustained for up to six hours. The study included 323 participants, randomised one-to-one into placebo and bilateral once-daily treatment with AGN-190584 for 30 days. 

Allergan reported the drops’ only adverse effect was headache in >5% of participants, with 1.2% of patients discontinuing treatment. 

For recent news on presbyopia drops, see https://eyeonoptics.co.nz/articles/archive/presbyopia-drops-draw-closer/